

NATIONAL ADVISORY COUNCIL CONCEPT CLEARANCE

Date of Council: February 3-4, 2020

Title of Initiative: Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations Experiencing Health Disparities

Author(s): Larissa Avilés-Santa, M.D., M.P.H. and Benyam Hailu, M.D., M.P.H.

Objectives: This initiative will support research to develop and test multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from populations experiencing health disparities and optimize patient engagement and self-management.

Background: Current national statistics reveal an overall prevalence of diabetes mellitus (all types) at 14.3% of the population [1]. The prevalence of diabetes mellitus among racial/ethnic minorities has consistently been significantly higher (more recently in the 20.6%-23.5% range or 2-3 times higher) than that of non-Hispanic Whites (NHWs) (11.3%), and is on the rise [1,2]. In addition, the prevalence of self-reported diabetes mellitus in rural areas is 17% higher than in metropolitan areas [3,4], 20-55% higher in SGM than non-SGM individuals [5,6], and inversely associated with income and socioeconomic status [1,7,8].

Although Type 2 diabetes (the most common form of diabetes mellitus) is strongly associated with cardiovascular (CV) complications (coronary artery disease, peripheral vascular disease, stroke and cardiomyopathy), it is also associated with long-term microvascular diseases (retinopathy, nephropathy, neuropathy, and others (e.g., hypoglycemia, infections, and pregnancy-related complications). Over the last decade, the association of diabetes with cognitive decline [9-11] and cancer [12-16] has gained attention. Therefore, comprehensive diabetes care guidelines for optimal glycemic control and prevention of complications have been established and are annually updated [17-26].

The limited existing data on diabetes-related complications in U.S. populations with health disparities point towards a significant risk and burden of complications. For instance, African Americans have four times, and Asians and Pacific Islanders have 1.5 times increased risk for diabetic retinopathy (DR) than NHWs. Individuals from rural settings may have 21% greater risk of DR than those living in urban settings [4]. The prevalence of DR in Hispanics/Latinos could be up to 46.9% and for American Indians/Alaska Natives 45.3% [4]. The NHANES trends during 1988-2010 showed that the percentage of African Americans, Mexican Americans and other Hispanics with hemoglobin A1c (A1C) <7% or <8%, or blood pressure 130/80 or <140/90, or LDL <100 mg/dL and/or on statin therapy, was significantly lower than NHWs [27]. Hispanic/Latinos, African Americans and American Indians/Alaska Natives have 1.3-1.5 times risk for major amputations than NHWs [28], and Medicaid beneficiaries have 21.1-25.1% increased odds of having major or minor amputations compared to Medicare beneficiaries [29]. On the other hand, African Americans and Hispanics/Latinos are 20-30% more likely to receive endovascular interventions or open bypass than NHWs, whereas American Indians are 40% less likely to receive either treatment [28].

In 2017, the American Diabetes Association reported that the U.S. annual cost of diabetes management totaled \$317 billion, which was attributed to \$237 billion in health care costs and \$90

billion in costs due to lost productivity [30]. Diabetes-related health care costs are mostly driven by hospitalizations [31-34], most of which are considered preventable [31,32,35,36]. Some racial/ethnic minority populations experience significantly increased odds for preventable hospitalizations [31,32,35,37], including higher than expected 30-day readmission rates for African Americans and Hispanics [31,35].

Completion rates of all or some of the recommended clinical assessments for persons with diabetes (e.g., A1C/lipid/blood pressure targets, annual retinal exam, foot exam, urine albumin and estimated glomerular filtration rate, influenza/pneumonia vaccines and others) [17-26] tend to be 10-30% lower for racial/ethnic minority populations than for NHWs [38-40]; 17% in rural settings [3] and 7-11% in the U.S. territories Puerto Rico, USVI and Guam [40]. These lower completion rates may in part explain the increased odds for preventable hospitalizations and readmissions mentioned above.

Patient-centered models of care, like the chronic care model (CCM), have been recommended as effective frameworks for optimal diabetes care [18,26,41-43]. The six elements of the CCM [20,41,42] include community resources/built environment (including policies), health care organization (quality-oriented culture), clinician decision support, clinical information system, patient self-management support (e.g., decision-making support, patient-clinician communication, patient-reported outcomes), and delivery system design (team-based, coordinated and proactive care). This framework has been expanded to address primary prevention of diabetes and incorporate future research into clinical practice [43].

Research Gaps: The implementation and effectiveness of the full CCM -or some variations- in the management of Type 2 diabetes has been studied in different populations and settings in the U.S. [42,45-55]. Significant improvement in clinical outcomes [42,45-48,55], cardiovascular risk score [47,48], and completion rates of recommended tests [50,53] have been demonstrated. At the same time, some studies have demonstrated improvement in glycemic control with the integration of cultural competence at the self-management [55] and community resources levels [48], but no consistently observed improvement with interventions at the delivery system level [48,55], low adherence at the clinician decision support level [49], and lack of effectiveness at the clinical information level [51]. In some of these studies, the percentage of patients from racial/ethnic minority groups ranged between 1% and 13% [44,45,47], and very few studies were dedicated to developing and testing the CCM or similar models of diabetes care for populations experiencing health disparities [46,53-55]. Among the latter, significant improvement in A1C, blood pressure, lipids and ACEI/aspirin/statin intake were observed among uninsured patients attending an acute care setting, most of whom were from racial/ethnic minority populations [46]. Other studies have evaluated culturally-tailored community-engagement interventions for Latinos without linking them to the health care system or clinician [53-55], primarily focusing on the self-management element.

Effective implementation of and adherence to recommended guidelines of care [e.g., assessment of risk of diabetes-related complications, setting optimal glycemic goals and control of CV risk factors, designing a treatment plan, medical/dental/nutritional referrals, immunizations and other preventive services] is urgently needed for individuals with diabetes from populations experiencing health disparities. Effective strategies would be expected to impact health across all populations in a positive way, while potentially generating new information and research hypotheses on treatment effectiveness and precision medicine.

Previous and ongoing NIH efforts in this area: The NIDDK has established the [NIDDK Diabetes Centers](#) program, which does not directly fund major research projects. The proposed initiative does not represent an overlap with this NIDDK program. The NIDDK has also issued the funding opportunity announcements (FOAs) *Evaluating Natural Experiments in Healthcare to Improve Diabetes Prevention and Treatment* ([PAR-17-178](#)), and *Addressing Health Disparities in NIDDK Diseases* ([PA-18-412](#)). The former FOA does not focus on the implementation and testing of health care delivery. Under the latter FOA no studies involving disparities in the implementation or comparative effectiveness of recommended diabetes care guidelines have been funded.

Other FOAs addressing implementation of health care delivery or promotion of patient adherence to treatment include: *Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health* ([PA-18-722](#)), *AHRQ Health Services Research Demonstration and Dissemination Grants (R18)* ([PA-18-793](#)), and *Dissemination and Implementation Research in Health* ([PAR-19-274](#)). None of these initiatives specifically looks at research in the implementation of diabetes care guidelines.

Description of the Initiative: This initiative will support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize Type 2 diabetes care for populations experiencing health disparities concordant with evidence-based guidelines. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEI/statin/ aspirin and influenza/pneumonia vaccines). The effect of the implementation of these strategies and guidelines on quality of life, optimal care of comorbidities, and prevention of short- and long-term complications, including hospitalizations, are also of interest.

Areas of interest and potential study designs include but are not limited to:

- Multi-level interventions that promote a proactive care delivery (consider health IT and comorbidities) – Identify intermediate factors that mediate or contribute to health or effectiveness of treatment outside of the clinical setting
- Interventions involving clinician decision support, adherence to recommended guidelines, patient/family unit decision-making, and adherence to treatment and self-management (especially for older adults)
- Innovative multi-level strategies to implement guidelines of care within the context of challenging housing- and/or work-related conditions or settings
- Health care coordination between traditional and non-traditional health care settings (e.g., pharmacies, fire stations, other community resources)
- Studies that evaluate the effectiveness of individualization of guidelines of care based on age (e.g., older adults), sex/gender, race/ethnicity, urban/rural settings, pregnancy status, comorbidities, and state of progression of the disease, including prioritization and integration of guidelines of care in the context of comorbidities
- Studies that address implicit bias strategies/practices across different levels in the health outcomes/care continuum
- Analyses and sub-analyses on sustainability, actual and/or projected health care costs, and prevention of hospitalizations and other complications. In addition, analyses of costs of interventions could assess the costs and access of medications, health care payer policies, health

insurance and health care system protocols and processes, availability of subspecialty care, and payment models.

References and Resources

1. Menke A, Casagrande SS, Cowie CC. Prevalence and trends in diabetes among adults in the United States, 1988-2012. *JAMA* 2015; 314: 1021-1029
2. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and American Indians/Alaska Natives (<https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=33>)
3. Hale NL, Bennett KJ, Probst JC. Diabetes care and outcomes: disparities across rural America. *J Community Health* 2010;35(4):365–374
4. Fathy C, Patel S, Sternberg P Jr, Kohanim S. Disparities in adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. *Sem Ophthalmol* 2016; 31: 364-377
5. Beach LB, Elasy TA, Gonzales G. Prevalence of self-reported diabetes by sexual orientation: results from the 2014 Behavioral Risk Factor Surveillance System. *LGBT Health* 2018; 5: 121-130
6. Caceres BA, Jackman KB, Edmondson D, Bockting WO. Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS. *J Behav Med* 2019; doi.org/10.1007/s10865-019-00102-8
7. Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P et al. Variations in diabetes prevalence in low-, middle-, and high-income countries: results from the Prospective Urban and Rural Epidemiological Study. *Diabetes Care* 2016; 39: 780-787
8. Mendenhall E, Kohrt BA, Norris SA, Ndeti D, Prabhakaran D. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. *Lancet* 2017; 389: 951-963
9. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. *Nat Rev Endocrinol* 2018; 14: 591-604
10. Simó R, Ciudin A, Simó-Servat O, Hernández C. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-the diabetologist's perspective. *Acta Diabetol* 2017; 54: 417-424
11. Nakabeppu Y, Nimomiya T. Diabetes mellitus: a risk factor for Alzheimer's disease. *Advances in Experimental Medicine and Biology* (book)
12. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer risk I: risk, survival, and implications for screening. *Cancer Causes Control* 2012; 23: 967-981
13. Seppälä LK, Vettenranta K, Pitkäneimi J, Hirvonen E, Leinonen MK, Madanat-Harjuoja LM. Maternal diabetes and risk of childhood cancer in the offspring. *Int J Cancer* 2019; doi: 10.1002/ijc.32757

14. Harding JL, Andes LJ, Gregg EW, Cheng YJ, Weir HK, Bullard KM, Burrows NR, Imperatore G. Trends in cancer mortality among people with vs without diabetes in the USA, 1988-2015. *Diabetologia* 2019; doi: 10.1007/s00125-019-04991-x.
15. Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. *Cancers* 2019; 11(9); doi: 10.3390/cancers11091402
16. Best LG, Garcia-Esquina E, Yeh JL, Zhang Y, et al. Association of diabetes and cancer mortality in American Indians: the Strong Heart Study. *Cancer Causes Control* 2015; 26: 1551-1560
17. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes -2019. *Diabetes Care* 2019; 42 (Suppl 1): S34-S45
18. American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes-2019. *Diabetes Care* 2019; 42 (Suppl 1): S7-S12
19. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2019; *Diabetes Care* 2019; 42 (Suppl 1): S124-S138
20. American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. *Diabetes Care* 2019; 42 (Suppl 1): S61-S70
21. American Diabetes Association. Cardiovascular disease risk management: standards of medical care in diabetes-2019. *Diabetes Care* 2019; 42 (Suppl 1): S103-S123
22. American Diabetes Association. Older adults: standards of medical care in diabetes-2019. *Diabetes Care* 2019; 42 (Suppl 1): S139-S147
23. American Diabetes Association. Management of diabetes in pregnancy: standards of medical care in diabetes-2020. *Diabetes Care* 2020; 43 (Suppl 1): S183-192
24. Garber AJ et al. Consensus statement by the American Association of Clinical Endocrinologists and the American College of Endocrinology on the comprehensive Type 2 diabetes management algorithm – 2018 Executive Summary. *Endocrine Practice* 2018; 24: 91-120
25. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-Executive Summary. *Endocrine Practice* 2017; 23: 479-497
26. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018; 41: 2669-2701
27. Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1c, blood pressure, and LDL goals among people with diabetes, 1988-2010. *Diabetes Care* 2013; 36: 2271-2279

28. Tze-Woei T, Chia-Ding S, Concha-Moore KC, Diri MM, Hu B, Marrero D, Zhou W, Armstrong DG. Disparities in outcomes of patients admitted with diabetic foot infections. *PLoS ONE* 2019; 14: e0211481
29. Skrepnek GH, Mills JL, Armstrong DG. A diabetic emergency one million feet long: disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006-2010. *PLoS ONE* 2015; 10: e0134914
30. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. *Diabetes Care* 2018; 41: 917-928.
31. Saundankar V, Ellis J, Allen E, DeLuzio T, Moretz C, Meah Y, Suehs B, Bouchard J. Type 2 diabetes mellitus patients' healthcare costs related to inpatient hospitalizations: a retrospective administrative claims database study. *Adv Ther* 2015; 32: 662-679
32. Tseng C-L, Soroka O, Pogach LM. An expanded prevention quality diabetes composite: quantifying the burden of preventable hospitalizations for older adults with diabetes. *J Diabetes Complications* 2018; 32: 458-464
33. Stockbridge EL, Chhetri S, Polcar LE, Loethen AD, Carney CP. Behavioral health conditions and potentially preventable diabetes-related hospitalizations in the United States: findings from a national sample of commercial claims data. *PLoS ONE* 2019; 14: e0212955
34. Meng Y-Y, Pickett MC, Babey SH, Davis AC, Goldstein H. Diabetes tied to a third of California hospital stays, driving health care costs higher. *UCLA Center for Health Policy Research* 2014; PB2014-3
35. Rodriguez-Gutierrez R, Herrin J, Lipska KJ, Montori VM, Shah ND, McCoy RG. Racial and ethnic differences in 30-day hospital readmissions among U.S. adults with diabetes. *JAMA Network Open* 2019; 2: e1913249 doi:10.1001/jamanetworkopen.2019.13249
36. Fu H, Curtis BH, Xie W, Festa A, Schuster DP, Kendall DM. Frequency and causes of hospitalization in older compared to younger adults with type 2 diabetes in the United States: a retrospective, claims-based analysis. *J Diabetes Complications* 2014; 28: 477-481
37. Sentell TL, Ahn HJ, Juarez DT, Tseng C-W, Chen JJ, Salvail FR, Miyamura J, Mau MLM. Comparison of potentially preventable hospitalizations related to diabetes among Native Hawaiian, Chinese, Filipino, and Japanese elderly compared with Whites, Hawai'i, December 2006-December 2010. *Prev Chronic Dis* 2013; 10.
38. Bennett KJ, McDermott S, Mann JR, Hardin J. Receipt of recommended services among patients with selected disabling conditions and diabetes. *Disabil Health J* 2017; 10: 58-64
39. Lundeen EA, Wittenborn J, Benoit SR, Saadine J. Disparities in receipt of eye exams among Medicare Part B Fee-for-Service beneficiaries with diabetes- United States, 2017. *MMWR Morb Mortal Wkly Rep* 2019; 68: 1020-1023.
40. Ogilvie RP, Patel SA, Narayan KMV, Mehta NK. Are the U.S. territories lagging behind in diabetes care practices? *Prim Care Diabetes* 2018; 12: 432-437

41. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. *Health Aff* 2001; 20: 64-78
42. Stefellson M, Dipnarine K, Stopka C. The chronic care model and diabetes management in U.S. primary care settings: a systematic review. *Prev Chronic Dis* 2013; 10: 120180
43. Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT. Dysglycemia-based chronic disease: an American Association of Clinical Endocrinologists position statement. *Endocrine Practice* 2018; 24: 995-1011
44. Siminerio LM, Platt G, Zgibor JC. Implementing the Chronic Care Model for improvements in diabetes care and education in a rural primary care practice. *Diabetes Educator* 2005; 31: 225-234
45. Piatt GA, Orchard TJ, Emerson S, Simmons D, Songer TJ, Brooks MM, Korytkowski M, Siminerio LM, Ahmad U, Zgibor JC. Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention. *Diabetes Care* 2006; 29: 811-817
46. Khan MA, Evans AT, Shah S. Caring for uninsured patients with diabetes: designing and evaluating a novel chronic care model for diabetes care. *J Eval Clin Pract* 2010; 16: 700-706
47. Vargas RB, Mangione CM, Asch S, Keesey J, Rosen M, Schonlau M, Keeler EB. Can a chronic care model collaborative reduce heart disease risk in patients with diabetes? *J Gen Intern Med* 2007; 22: 215-222
48. Parchmann M, Kaissi AA. Are elements of the chronic care model associated with cardiovascular risk factor control in type 2 diabetes? *Jt Comm J Qual Patient Saf* 2009; 35: 133-138
49. Smith SA, Shah ND, Bryant SC, Christianson TJ, Bjornsen SS, Giesler PD, Krause K, Erwin PJ, Montori VM, Evidens Research Group. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. *Mayo Clin Proc* 2008; 83: 747-757
50. Hariharan J, Tarima S, Azam L, Meurer J. Chronic care model as a framework to improve diabetes care at an academic internal medicine faculty-resident practice. *J Ambulatory Care Manage* 2014; 37: 42-50
51. Mallow JA, Theeke LA, Barnes ER, Whetsel T, Mallow BK. Using mHealth tools to improve rural diabetes care guided by the Chronic Care Model. *J Rural Nurs Health Care* 2014; 14: 43-65
52. Mills WR, Poltavski D, Douglas M, Owens L, King A, Roosa J, Pridham J, Dzina D, Weber D. A platform and clinical model to enable Medicare's chronic care management program. *Population Health Management* 2019; doi: 10.1089/pop.2019.0053
53. Liebman J, Heffernan D, Sarvela P. Establishing diabetes self-management in a community health center serving low-income Latinos. *Diab Educator* 2007; 33: 132S-138S
54. Philis-Tsimikas A, Gallo LC. Implementing community-based diabetes programs: the Scripps Whittier Diabetes Institute experience. *Curr Diab Rep* 2014; 14: 462

55. Dauvrin M, Lorant V, d'Hoore W. Is the chronic care model integrated into research examining culturally competent interventions for ethnically diverse adults with type 2 diabetes mellitus? A review. *Evaluation & Health Professions* 2015; 38: 435-463